| Patent application number | Description | Published |
|---|
| 20080307438 | STATUS HUB USED BY AUTONOMIC APPLICATION SERVERS - A method for serving applications including receiving a component status publication and acquiring a client request. The component status publication can specify a usage level for an application component. A server response for the client request can be selected from among a multitude of possible server responses based at least in part upon the component status publication. Each possible server response can differentially utilize application components. The client request can be response to by conveying the selected server response. | 12-11-2008 |
| 20090083749 | RESTRICTING RESOURCES CONSUMED BY GHOST AGENTS - One aspect of the present invention can include a method for restricting resources consumed by ghost agents. The method can include the step of associating a ghost agent with a host. A resource utilization value can be ascertained for the ghost agent and the host combined. The ascertained resource utilization value can be compared with a usage threshold. A determination can be made as to whether operations of the ghost agent are to be executed based upon the previous comparison. | 03-26-2009 |
| 20090106420 | GHOST AGENTS FOR APPLICATION DOMAINS WITHIN A GRID ENVIRONMENT - A method for evaluating system behavior of an application domain within a grid environment can include the step of identifying a host software object within the application domain. A software object can be associated with the host software object. Within the associated software object, host actions can be replicated. Replicated actions can be recorded. The host software object can move from one grid within the grid environment to a different grid. The associated software object can responsively move within the grid environment in accordance with movement of the host software object. | 04-23-2009 |
| 20090112565 | TESTING APPLICATIONS WITHIN A GRID ENVIRONMENT USING GHOST AGENTS - A testing method including the step of identifying multiple hosts located within multiple grids of a grid environment, wherein each host is a software object. A ghost agent can be associated with each identified host. Actions of the host can be replicated within each ghost agent. Data relating to the replicated actions can be recorded. Test input can be generated from the recorded data. Tests can be conducted within the grid environment using the test input. | 04-30-2009 |
| 20090113190 | GATHERING OPERATIONAL METRICS WITHIN A GRID ENVIRONMENT USING GHOST AGENTS - A method for gathering operational metrics can include the step of identifying a host within a grid environment, wherein the host can be a software object. A ghost agent can be associated with the host. The ghost agent can replicate actions of the host. Operational metrics for at least a portion of the replicated actions can be determined. The operational metrics can be recorded. The host can move within the grid environment. The ghost agent can responsively move in accordance with movement of the host. | 04-30-2009 |
| 20090113395 | VALIDATING SOFTWARE IN A GRID ENVIRONMENT USING GHOST AGENTS - A validation method can include the step of identifying a host within a grid environment, wherein the host is a software object. A ghost agent can be associated with the host, where the ghost agent can move within the grid environment. The actions of the host can be replicated by the ghost agent. Data related to the replicated actions can be compared with validation data. Validation output can be generated based upon the comparison. | 04-30-2009 |
| 20090119544 | GHOST AGENTS WITHIN A GRID ENVIRONMENT - A method for evaluating system behavior within a grid environment can include the step of identifying a host software object, wherein the host software object includes a user object, an application, and/or a process. The software object can be associated with the host software object. The host actions of the host software object can be replicated within the associated software object. Replicated actions can be recorded. The host software object can move from one grid within the grid environment to a different grid. In response to the moving of the host software object, the associated software object can move from the one grid to the different grid. | 05-07-2009 |
| Patent application number | Description | Published |
|---|
| 20090004213 | COMBINATION THERAPY USING ACTIVE IMMUNOTHERAPY - The present invention relates to methods of treating cancer in a mammal comprising administering to the mammal a combination therapy comprising a vaccine and a multi-kinase inhibitor, wherein the vaccine comprises an isolated tumor associated peptide having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or class-II. Preferably the multi-kinase inhibitor is sunitinib malate and/or sorafenib tosylate or a pharmaceutically acceptable salt thereof. | 01-01-2009 |
| 20090123489 | NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 05-14-2009 |
| 20090136528 | NOVEL IMMUNOGENIC EPITOPE FOR IMMUNOTHERAPY - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 05-28-2009 |
| 20090148400 | COMPOSITION OF TUMOUR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE - The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumour immune responses against colorectal cancer. | 06-11-2009 |
| 20100158931 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 06-24-2010 |
| 20110002963 | COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GLIOBLASTOMA (GBM) AND OTHER CANCERS - The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas. | 01-06-2011 |
| 20110117117 | NOVEL IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 05-19-2011 |
